Dbv technologies: Share decline, green light from Xolair in the USA

(CercleFinance.com) – DBV Technologies fell by almost 2% on Monday on the Paris Stock Exchange in the wake of the green light granted by the American health authority (FDA) to the marketing of Xolair, Roche’s treatment for food allergies .

On Friday, Roche announced that the FDA had authorized the marketing in the United States of Xolair for children and adults suffering from food allergies following accidental exposure.

This green light comes as results from a phase III study showed that Xolair significantly increased the amount of peanut, milk, egg and cashew nuts needed to cause an allergic reaction.

In the United States, 17 million people have confirmed food allergies, and more than 40% of children and more than 50% of adults with allergies have had a severe reaction at least once in their life.

‘DBV, which was the best positioned player in this field, is being overtaken,’ deplore Invest Securities analysts this morning, who point out that the French company was forced to relaunch a new phase III study to meet the requirements. recommendations from the FDA and EMA.

This trial having only started at the beginning of 2022, the results are not expected before 2025, which implies a launch on the market at the earliest in 2026, adds the brokerage company.

Invest Securities also points out that the patches developed by DBV only address a single food allergy, unlike Xolair which limits the allergic reaction.

Analysts also point out that DBV’s financial resources are lower than those of Roche, which can rely on an already well-established commercial network unlike DBV.

However, the DBV patch, if it were to be approved, could prove less expensive to produce and therefore less expensive to sell, continues Invest.

‘It could also benefit from another advantage in terms of method of administration, especially in young children, since the patch is applied once a day to the subject’s back compared to an injection by syringe for Xolair.’ , concludes the Parisian firm.

Copyright (c) 2024 CercleFinance.com. All rights reserved.